Plasma Fractionation Market Scope And Analysis

Buy Now

Plasma Fractionation Market Analysis, Scope, and Growth by 2028

Buy Now

Report Attribute	Details
Market size in 2021	US$ 26.58 Billion
Market Size by 2028	US$ 40.73 Billion
Global CAGR (2021 - 2028)	6.3%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Product Immunoglobulin Albumin Coagulation Factor Concentrates Protease Inhibitors Other Plasma Products By Application Neurology Immunology Hematology Critical Care Pulmonology Other Applications By End User Hospitals and Clinics Clinical Research Laboratories Academic Institutes
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	BASF SE TMIC Creative Proteomics BGI RTI International Afekta Technologies Ltd Fred Hutchinson Cancer Research Center West Coast Metabolomics Center Molecular You

Companies in the plasma fractionation market highly adopt inorganic and organic strategies. A few recent key market developments are listed below:

In April 2020, Grifols, a global manufacturer of plasma-derived medicines, announced the launch of a new 3-mL vial of HyperRAB, which is used to treat postexposure prophylaxis for rabies. The US Food and Drug Administration had already approved this vial in 2019.
In May 2021, Liminal BioSciences Entered into an Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business.
In April 2021, BPL and Atlantic Research Group entered into a long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs.